Pulmonary Embolism Prophylaxis in Patients With COVID-19: An Emerging Issue

Severe acute respiratory syndrome (SARS)-CoV-2 virus disease (coronavirus disease 2019; COVID-19) is associated with increased coagulation activity, resulting in an excessive risk of venous thromboembolism (VTE) and poor prognosis. The most common manifestation of VTE is pulmonary embolism (PE), wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanidas, Elias, Grassos, Charalampos, Papadopoulos, Dimitrios, Velliou, Maria, Barbetseas, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). Published by Elsevier B.V. 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8114761/
https://www.ncbi.nlm.nih.gov/pubmed/34049806
http://dx.doi.org/10.1016/j.hlc.2021.04.018
Descripción
Sumario:Severe acute respiratory syndrome (SARS)-CoV-2 virus disease (coronavirus disease 2019; COVID-19) is associated with increased coagulation activity, resulting in an excessive risk of venous thromboembolism (VTE) and poor prognosis. The most common manifestation of VTE is pulmonary embolism (PE), with approximately one in five hospitalised patients being at risk. These reports led to the empirical use of prophylactic anticoagulation, even in the absence of established or clinically suspected disease. This review summarises current aspects and recommendations regarding the use of thromboprophylaxis for PE in patients with COVID-19.

Ejemplares similares